How many clinical trials are studying Bimekizumab?

5 recruiting trials in our tracked data involve Bimekizumab.

What conditions is Bimekizumab being studied for?

In our tracked recruiting trials, Bimekizumab is being studied in trials for Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis.

Bimekizumab: clinical trials recruiting now

Q: Is Bimekizumab FDA-approved?

Yes. According to the FDA drug label available through openFDA, Bimekizumab is an FDA-approved drug.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA drug label

FDA-approved: Yes. Bimekizumab appears in the FDA drug-label database. Marketed as Bimzelx.

FDA-approved use

BIMZELX is a humanized interleukin-17A and F antagonist indicated for the treatment of: Moderate to severe plaque psoriasis (PSO) in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) Adults with active psoriatic arthritis (PsA) . ( 1.2 ) Adults with active non-radiographic axial spondyloarthritis ( nr-axSpA ) with objective signs of inflammation. ( 1.3 ) Adults with active ankylosing spondylitis ( AS ). ( 1.4 ) Adults with moderate to severe hidradenitis suppurativa (HS) . ( 1.5 ) 1.1 Plaque Psoriasis BIMZELX is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. 1.2 Psoriatic Arthritis BIMZELX is indicated for the treatment of adults with active psoriatic arthritis. 1.3 Non-Radiographic Axial Spondyloarthritis BIMZELX is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. 1.4 Ankylosing Spondylitis BIMZELX is indicated for the treatment of adults with active ankylosing spondylitis. 1.5 Hidradenitis Suppurativa BIMZELX is indicated for the treatment of adults with moderate to severe hidradenitis suppurat…

FDA label via openFDA

Phase breakdown

Phase 1 1 Phase 2 2 Phase 3 1 Not applicable 1

Conditions being studied

Condition	Trials
Psoriasis · Bimekizumab for Psoriasis	5
Psoriatic Arthritis	2
Axial Spondyloarthritis	1
Depression	1
Hidradenitis Suppurativa	1
Lupus	1
Moderate to Severe Plaque Psoriasis	1
Palmoplantar Pustulosis	1
Psoriatic Plaque	1
Rheumatic Disease	1
Rheumatoid arthritis	1

Recruiting trials involving Bimekizumab

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
NCT06888193 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Female · 14 locations
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
NCT07219420 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 91 locations
Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?
NCT06742333 · Phase: Phase 2 · Ages: 18 Years to 45 Years · Sex: All (male and female) · 7 locations
Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms
NCT06786936 · Phase: Not specified · Ages: 18 Years to 74 Years · Sex: All (male and female) · 2 locations
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
NCT07138898 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations

Common questions

Is Bimekizumab FDA-approved?

Yes, marketed as Bimzelx.

How many recruiting trials involve Bimekizumab?

5 recruiting trials across 11 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.